Locations: 
London (University College Hospital)

This trial is for patients who need to take the drug denosumab for more than a year. It will look at the risks and benefits of taking 120g of denosumab every 12 weeks rather than every four weeks. 

Full title: Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE"

Age: 18+
Status: Open
Phase: 2

This trial looks at the risks and benefits of taking 120g of denosumab every 12 weeks rather than every 4 weeks in patients who need to take this drug for more than a year. Participants must have taken at least 12 doses of denosumab and may have taken up to 15 doses before joining this trial.